Following up on our May 30, 2007 posting, MedImmune has finally settled its lawsuit with Genentech over a patented component of Synagis, MedImmune’s best-selling drug, which is aimed at preventing respiratory infections in infants, according to a report by the Washington Post.  The settlement comes just over a year after the Supreme Court decision was issued allowing MedImmune to challenge the validity of the Genentech patent while continuing to pay royalties incurred in a license agreement with Genentech. 

No details of the settlement have been released thus far; however, the parties are reported to be filing a stipulation of dismissal in the next few weeks.

Related posts:

1. Another Look at MedImmune v. Genentech
2. Genentech Claims Rejected on Patent Which Was Subject of Recent Supreme Court Decision
3. Genentech Hit with Adverse Patent Ruling
4. California Supreme Court Overturns Punitive Damage Award Against Genentech
5. Seventh Circuit Rules in favor of WARF in Licensing Dispute with Xenon Pharmaceuticals